Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
According to the World Health Organization the average globa
2022-06-21

According to the World Health Organization, the average global intake of fat has increased by 20 g per person over the last half-century [21]. However, not all fats are the same and it is now well established that saturated and unsaturated fats, as well as trans fats, can act in opposing ways to inf
-
br Materials and methods br
2022-06-21

Materials and methods Results Discussion FFAR4 is a G-protein coupled free fatty Tirapazamine sale receptor that has been reported to be expressed in osteoclasts and osteoblasts [18]. In this study the role of FFAR4 on the effects of different classes of UFAs, the ω−6 PUFA, AA, the ω−3 PUFA
-
Compound and several additional FPR
2022-06-21

Compound 10 and several additional FPR1 antagonists identified here specifically blocked fMLF-induced responses mediated via FPR1 in FPR1-HL60 Veliparib dihydrochloride sale and human neutrophils, but not responses mediated via FPR2 or FPR3 (in human neutrophils and transfected HL60 cells) or Fpr1 (
-
In summary PPARG and FFAR are connected in several ways
2022-06-21

In summary, PPARG and FFAR1 are connected in several ways, and the presented interaction is mechanistically reasonable. Additional investigations are required to elucidate the exact details of the underlying physiology. However, our findings are of immanent importance for the treatment of type 2 dia
-
br Ferroptosis modulators With the recognition that the smal
2022-06-21

Ferroptosis modulators With the recognition that the small molecule erastin targets system xc- and thereby specifically triggers this form of death and that ferrostatin-1 prevents erastin-induced ferroptosis [2], it has become evident that ferroptosis is a druggable pathway with a number of tract
-
The release of FBPase and aldolase from
2022-06-21

The release of FBPase and aldolase from subcellular structures of muscle was dependent on the presence of the crowding agent imitating the physiological conditions – PEG 8000 (Table 1). The amount of both enzymes associated with structures of muscle CH 223191 sale was about 6–7 times higher in the
-
This profound cell type specificity
2022-06-20

This profound cell-type specificity of G9a/GLP complex modulation of neuronal plasticity is accentuated by studies employing genetic ablation of G9a in dopamine 1 receptor (Drd1)- and dopamine 2 receptor (Drd2)-expressing medium spiny neurons (MSNs) in the nucleus accumbens (NAc). Conditional G9a kn
-
The only approved H R antagonist inverse
2022-06-20

The only approved H3R antagonist/inverse agonist is BF2.649 (1- 3-[3-(4-chlorophenyl)propoxy]propyl piperidine), developed by Bioprojet and known as pitolisant (Wakix®). It was approved by the European Medicines Agency in March 2016 and marketed in the European Union to be used in narcolepsy with or
-
To verify DNA glycosylase AP lyase activity we have employed
2022-06-20

To verify DNA glycosylase/AP lyase activity we have employed a simple and efficient method to investigate based on fluorescein-labeled duplex oligonucleotides read on an automated sequencer (Allgayer et al., 2013, Lopes et al., 2007, Lopes et al., 2008). This approach using purified CpMutY proteins
-
br Conclusion br Conflict of interest statement br Acknowled
2022-06-20

Conclusion Conflict of interest statement Acknowledgements This work was supported by the National Science Foundation (MCB-1817417 to S.D.) and National Institutes of Health (R01-GM72711 to A.C.D.). We thank members of the Delaney laboratory for careful reading of the manuscript and helpful
-
Na K ATPase adenosine triphosphate
2022-06-20

Na+/K+-ATPase, Chlorambucil and astrocytic glutamate transporters act together to maintain sodium and potassium gradients and the proper activities of EAAT1 and EAAT2 (Rose et al., 2009; Sheean et al., 2013); nevertheless, in present study, Na+/K+-ATPase activity was shown to be increased as from 2
-
The effect of on the
2022-06-18

The effect of on the conformational of G-quadruplexes was investigated with circular dichroism (CD) spectroscopy. In the absence of , the CD spectra of parallel G-quadruplex exhibited a characteristic positive peak at about 265 nm, and a negative peak at about 240 nm; antiparallel G-quadruplex showe
-
Statins are recognized by their nephroprotective effect
2022-06-18

Statins are recognized by their nephroprotective effect (Chmielewski et al., 2002). The hepato- and nephroprotective effects of silymarin are also well studied (Alqasoumi, 2014, Mohamed et al., 2018). Several studies documented increasing Nitrendipine of FXR by statins (Byun et al., 2014& (Lu et al
-
Stimulation of FPR by bacterial
2022-06-18

Stimulation of FPR by bacterial N-formyl peptides induces basophil and mast TG003 release of immunogenic compounds such as histamine [21], [31]. Furthermore, we demonstrated that histamine plays a role in F-MITs-induced sepsis-like symptoms since cimetidine, a histamine H2-receptor antagonist, comp
-
br Conflicts of interest br Acknowledgments This work was
2022-06-18

Conflicts of interest Acknowledgments This work was supported by the Project of Huzhou Municipal Science and Technology Bureau of Zhejiang Province (No. 2016GY45 to YGC) and he Project of Zhejiang Basic Public Benefit research of Zhejiang Province (No. LGF18H160005 to YGC) Introduction Wit
15994 records 452/1067 page Previous Next First page 上5页 451452453454455 下5页 Last page